PERSEUS-IT. A Prospective Non-intERventional Study to asSEss the Effectiveness of Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 30 May 2017
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms PERSEUS-IT
- Sponsors Bayer
- 25 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Jun 2016 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2018.
- 11 Jan 2016 Planned primary completion date changed from 1 Aug 2018 to 1 Sep 2018 as reported by ClinicalTrials.gov.